Phase 4 N=29 Lemborexant Shift Work Treatment Study
Shift-Work Related Sleep Disturbance
Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Effects of Daytime Eszopiclone Administration in Shift Workers
Shift-Work Sleep Disorder
Primary: Nighttime Wakefulness Assessed by Mean Sleep Latency Across 4 Maintenance of Wakefulness Tests — 11.0; 14.75 minutes
Phase 4 N=383 Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
Excessive Sleepiness
Primary: Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at…
Phase 4 N=19 Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
Sleep Disorder, Shift-Work
Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05
N/A N=11 Ramelteon for a Nap Prior to a Night Shift
Healthy
Primary: Sleep Efficiency — 89.1; 83.3 percent
N/A N=16 Sleep Length and Circadian Regulation in Humans
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=34 Glasses for Adolescent Delayed Sleep-Wake Phase Disorder
Delayed Sleep-Wake Phase Disorder
Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours
N/A N=1,189 Fire Fighter Fatigue Management Program: Operation Healthy Sleep
Shift-Work Sleep Disorder · Insomnia · Restless Leg Syndrome
Primary: Firefighters' Health, as Determined by Number of 'Sick' Days Over 12 Months — 3.1; 3.2; 1.4; 2.6 days/firefighter — p=0.66
Phase 3 N=254 Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
Excessive Sleepiness · Shift Work Sleep Disorder
Primary: Multiple Sleep Latency Test (MSLT) — 3.1; 0.4 Minutes — p=<0.0001
N/A N=118 Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
Phase 3 N=328 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
Narcolepsy · Sleep Apnea, Obstructive · Sleep Apnea Syndromes
Primary: Safety and Tolerability as Measured by Number of Participants With Adverse Events — 323 Participants
N/A N=142 Delayed Sleep Timing in Teens Study
Delayed Sleep Phase
Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018
N/A N=40 Escitalopram Treatment of Night Eating Syndrome
Night Eating Syndrome
Primary: Night Eating Questionnaire — -13.0; -10.6 units on a scale
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
N/A N=15 Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Feasibility of Recruitment and Retention — 8; 6; 8; 6 participants
N/A N=121 A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes
Mental Disorders
Primary: Impairment (Sheehan Disability Scale) — 14.30; 12.03; 11.76; 6.57 score on a scale — p=0.025
Phase 3 N=40 The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder
Delayed Sleep Phase Syndrome
Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510
N/A N=12 Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
Phase 4 N=40 Randomized Controlled Trial on the Treatment Effects of Melatonin and Light Therapy on Delayed Sleep Phase Syndrome
Delayed Sleep Phase Syndrome
Primary: To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log…
N/A N=36 Validation of Safety and Efficacy for Night Shift Therapy
Obstructive Sleep Apnea
Primary: Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events — 100 Percentage of participants
N/A N=19 The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS
Sleep Disturbance · Insomnia · Acute Coronary Syndrome
Primary: Percentage of Participants Who Complete 100% of the Outcome Assessments at Study Conclusion — 4; 7; 5 Participants
N/A N=44 Are Bright Lights and Regulated Sleep Effective Treatment for Depression?
Sleep Phase Rhythm Disturbance · Sleep Deprivation
Primary: 17-Item Hamilton Rating Scale for Depression Score (Independent Evaluator) — 8.66; 10.46 units on a scale
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
N/A N=46 Individually Tailored Lighting System to Improve Sleep in Older Adults
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
N/A N=7 Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17